INmune Bio Reports Early Alzheimer’s Imaging Data Showing XPro’s Treatment Effects
Event summary
- INmune Bio will present Phase 2 imaging data for XPro in early Alzheimer’s disease at AAIC on July 12, 2026.
- Advanced MRI analyses showed statistically significant treatment-related changes in white matter myelin integrity (p < 0.01) and cortical microstructure at Week 24.
- Larger effects observed in patients selected using the company’s biomarker enrichment strategy.
- XPro received FDA Fast Track designation and completed an End-of-Phase 2 meeting with regulatory alignment.
The big picture
INmune Bio’s presentation at AAIC underscores the growing emphasis on neuroinflammation as a therapeutic target in Alzheimer’s disease. The Phase 2 imaging data for XPro align with broader industry trends toward precision medicine, where biomarker-driven patient stratification is becoming critical for clinical success. With regulatory alignment secured and Fast Track designation in place, INmune Bio is positioning itself to accelerate the development of its DN-TNF platform.
What we're watching
- Clinical Validation
- Whether the observed imaging biomarkers will translate into measurable clinical benefits in later-stage trials.
- Regulatory Pathway
- The pace at which INmune Bio advances XPro through its planned Phase 2b/3 registrational program following positive Phase 2 data.
- Biomarker Strategy
- How the company’s biomarker enrichment approach will impact patient selection and treatment efficacy in future studies.
Related topics